研究单位：[1]Shanghai Huanshan Hospital Fudan University-Dermatology[2]Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.[3]Huashan Hospital Fudan University,Shanghai,Shanghai,China,200040[4]Shanghai Dermatology Hospital,Shanghai,Shanghai,China,200050[5]The First Affiliated Hospital of Kunming Medical University,Kunming,Yunnan,China,650000
研究目的：
The purpose of this study is to determine the efficacy and safety of the study drug recombinant anti-IL-17A humanized monoclonal antibody in Chinese participants with moderate-to-severe plaque psoriasis.
